Murat Gökalp

This single-arm, double-blinded, core-laboratory adjudicated, prospective trial, conducted across four European centers between August 2019 and April 2022, investigates whether CCTA and FFR-CT are able to exclude hemodynamically significant coronary stenoses in patients with high-risk NSTE-ACS.

This registry-based observational study compares surgical and percutaneous revascularization in patients with multivessel disease who underwent treatment for non-ST-segment elevation myocardial infarction (NSTEMI), utilizing data extracted from the SWEDEHEART registry.

Compared to fluoroscopy guidance, routine use of ultrasound for large-bore transfemoral access in complex PCI did not significantly reduce clinically relevant bleeding or vascular complications. However, it notably improved first-pass puncture success, with a very low crossover rate.

The current subanalysis of the BioVasc trial offers valuable insights into the long-term effects of ICR versus SCR strategies in STEMI patients with MVD. The findings support current guidelines on the necessity of revascularizing non-culprit lesions.